NurExone Biologic (NRX) Stock Statistics & Valuation Metrics

NurExone Biologic has a market cap or net worth of C$40.37M. The enterprise value is C$51.62M.

NurExone Biologic has 73,395,850 shares outstanding. The number of shares has decreased by -2.65% in one year.

NurExone Biologic’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of NurExone Biologic is ―. NurExone Biologic’s PEG ratio is ―.

In the last 12 months, NurExone Biologic had revenue of ― and earned 15.00B in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

NurExone Biologic pays an annual dividend of ―, resulting in a dividend yield of ―

NurExone Biologic upcoming earnings date is Sep 2, 2026, TBA (Confirmed).

NurExone Biologic as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, NurExone Biologic has paid ― in taxes.

NurExone Biologic EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

NurExone Biologic has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for NurExone Biologic is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy